Arnuity Ellipta FDA Approval History
FDA Approved: Yes (First approved August 20, 2014)
Brand name: Arnuity Ellipta
Generic name: fluticasone furoate
Dosage form: Inhalation Powder
Company: GlaxoSmithKline
Treatment for: Asthma, Asthma, Maintenance
Arnuity Ellipta (fluticasone furoate inhalation powder) is a once-daily inhaled corticosteroid for the maintenance treatment of asthma.
Development timeline for Arnuity Ellipta
| Date | Article |
|---|---|
| May 24, 2018 | Approval GSK Receives FDA Approval of Arnuity Ellipta for Asthma in Children From 5 Years of Age |
| Aug 21, 2014 | Approval FDA Approves Arnuity Ellipta (fluticasone furoate) for the Treatment of Asthma |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
